Last update May 14, 2024

Вортиоксетина Гидробромид

Compatible

Safe substance and/or breastfeeding is the best option.

Antidepressant effects similar to other selective serotonin-reuptake inhibitors. Oral administration once daily.

Its pharmacokinetic data (high percentage of plasma protein binding and high volume of distribution) explain the negligible passage into milk observed. (Kiribayashi 2024, Marshall 2021, Monfort 2021)

No problems have been observed in infants whose mothers have taken it. (Kiribayashi​​​​​​​ 2024, Marshall 2021, Monfort 2021)

It can cause hyperprolactinemia and galactorrhea. (Verma 2017)


See below the information of this related product:

  • Maternal Depression (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Вортиоксетина Гидробромид is Vortioxetine Hydrobromide in Cyrillic.

Is written in other languages:

Groups

Вортиоксетина Гидробромид belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Вортиоксетина Гидробромид in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 75 %
Molecular weight 379 daltons
Protein Binding 98 - 99 %
VD 36 l/Kg
Tmax 7 - 11 hours
T½ 66 hours
M/P ratio 0.81 -
Theoretical Dose 0.002 - 0.008 mg/Kg/d
Relative Dose 0.32 - 1.7 %

References

  1. Kiribayashi M, Suda T, Takahashi M, Ishikawa M, Watanabe R, Ishioka K, Nakamura S, Kushiyama A. Vortioxetine Exposure During Pregnancy and Lactation: A Japanese Case Study of Neonatal Implications and Quantitative Milk and Plasma Analyses. Breastfeed Med. 2024 May 10. Consulted on May 14, 2024 Abstract
  2. Verma A, Kumar A. Risks Associated with Vortioxetine in the Established Therapeutic Indication. Curr Neuropharmacol. 2021;19(5):711-717. Abstract Full text (link to original source)
  3. Marshall K, Datta P, Rewers-Felkins K, Krutsch K, Baker T, Hale TW. Transfer of the Serotonin Modulator Vortioxetine into Human Milk: A Case Series. Breastfeed Med. 2021 Apr 16. Abstract
  4. Monfort A, Jutras M, Martin B, Boucoiran I, Ferreira E, Leclair G. Simultaneous quantification of 19 analytes in breast milk by liquid chromatography-tandem mass spectrometry (LC-MS/MS). J Pharm Biomed Anal. 2021 Sep 10;204:114236. Abstract
  5. EMA. Vortioxetina. Ficha técnica. 2016 Full text (in our servers)
  6. EMA. Vortioxetine. Drug Summary. 2016 Full text (in our servers)
  7. Areberg J, Petersen KB, Chen G, Naik H. Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. Basic Clin Pharmacol Toxicol. 2014 Abstract Full text (link to original source)

Total visits

1,900

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM